{
    "nct_id": "NCT05672355",
    "official_title": "Randomized Observer-Blinded Phase 2 Trial of COVID-19 Booster With GEO-CM04S1 or mRNA Vaccine in Patients With Chronic Lymphocytic Leukemia",
    "inclusion_criteria": "* Documented informed consent of the participant and/or legally authorized representative\n* Age: >= 18 years\n* Eastern Cooperative Oncology Group (ECOG) =< 1\n* Histologically confirmed diagnosis of CLL according to World Health Organization (WHO) classification\n* Prior COVID-19 Vaccination (2 or more Pfizer or Moderna) with last injection >= 3 months prior\n* Fully recovered from the acute toxic effects (except alopecia) to =< Grade 1 to prior anti-cancer therapy\n* White Blood Cells (WBC) >= 1,000/mm^3 (To be performed within 14 days prior to Day 1 of protocol therapy)\n* Platelets >= 50,000/mm^3 (To be performed within 14 days prior to Day 1 of protocol therapy)\n* Total bilirubin =< 1.5 X upper limit of normal (ULN) (unless has Gilbert's disease) (To be performed within 14 days prior to Day 1 of protocol therapy)\n* Aspartate aminotransferase (AST) =< 2.5 x ULN (To be performed within 14 days prior to Day 1 of protocol therapy)\n* Alanine transaminase (ALT) =< 2.5 x ULN (To be performed within 14 days prior to Day 1 of protocol therapy)\n* Creatinine clearance <1.5 ULN (To be performed within 14 days prior to Day 1 of protocol therapy)\n* Women of childbearing potential (WOCBP): negative urine or serum pregnancy test (To be performed within 14 days prior to Day 1 of protocol therapy)\n\n  * If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required\n* Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 6 weeks after the last vaccine injection\n\n  * Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only)\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Known current SARS CoV-2 infection\n* Prior Evusheld or other anti-SARS CoV-2 prophylaxis < 2 weeks prior\n* Prior hematopoietic cell transplantation (HCT) or chimeric antigen receptor (CAR) T cell therapy within the previous year\n* Systemic corticosteroids required for chronic conditions at doses > 0.5mg/kg/day prednisone equivalent within 7 days of enrollment\n* Intensive cytotoxic therapies, T-cell depleting therapies, within 30 days of enrollment; however, patients with stable disease on maintenance therapies are allowed (See ConMeds for lists of acceptable and contraindicated therapies)\n* Participants who have had a live vaccine =< 30 days prior to administration of any dose of study vaccine or subjects who are =< 2 weeks within administration of inactivated vaccines (e.g., influenza vaccine). Flu shots are allowed > 2 weeks before a study vaccine injection and > 2 weeks post study vaccine injection\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent (e.g., egg allergies)\n* Active infection not controlled on appropriate therapy\n* History of adverse event with a prior smallpox vaccination\n* History of pericarditis or myocarditis\n* Any MVA vaccine or poxvirus vaccine in the last 12 months\n* Females only: Pregnant or breastfeeding\n* Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures\n* Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)",
    "miscellaneous_criteria": ""
}